Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

Autor: Needham, EJ, Ren, AL, Digby, RJ, Norton, EJ, Ebrahimi, S, Outtrim, JG, Chatfield, DA, Manktelow, AE, Leibowitz, MM, Newcombe, VFJ, Doffinger, R, Barcenas-Morales, G, Fonseca, C, Taussig, MJ, Burnstein, RM, Samanta, RJ, Dunai, C, Sithole, N, Ashton, NJ, Zetterberg, H, Gisslén, M, Edén, A, Marklund, E, Openshaw, PJM, Dunning, J, Griffiths, MJ, Cavanagh, J, Breen, G, Irani, SR, Elmer, A, Kingston, N, Summers, C, Bradley, JR, Taams, LS, Michael, BD, Bullmore, ET, Smith, KGC, Lyons, PA, Coles, AJ, Menon, DK, Cambridge NeuroCOVID Group the CITIID-NIHR COVID-19 BioResource Collaboration and Cambridge NIHR Clinical Research Facility

Publikováno v: Needham, E J, Ren, A L, Digby, R J, Norton, E J, Ebrahimi, S, Outtrim, J G, Chatfield, D A, Manktelow, A E, Leibowitz, M M, Newcombe, V F J, Doffinger, R, Barcenas-Morales, G, Fonseca, C, Taussig, M J, Burnstein, R M, Samanta, R J, Dunai, C, Sithole, N, Ashton, N J, Zetterberg, H, Gisslén, M, Edén, A, Marklund, E, Openshaw, P J M, Dunning, J, Griffiths, M J, Cavanagh, J, Breen, G, Irani, S R, Elmer, A, Kingston, N, Summers, C, Bradley, J R, Taams, L S, Michael, B D, Bullmore, E T, Smith, K G C, Lyons, P A, Coles, A J & Menon, D K 2022, ' Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses ', Brain research, pp. awac321 . https://doi.org/10.1093/brain/awac321

COVID-19 is associated with neurological complications including stroke, delirium and encephalitis. Furthermore, a post-viral syndrome dominated by neuropsychiatric symptoms is common, and is seemingly unrelated to COVID-19 severity. The true frequen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3b4f8b8d62eaefb16e3088e5633685
https://doi.org/10.1093/brain/awac321

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Autor: Havrdova, E, Arnold, DL, Cohen, JA, Hartung, HP, Fox, EJ, Giovannoni, G, Schippling, S, Selmaj, KW, Traboulsee, A, Compston, DAS, Margolin, DH, Thangavelu, K, Panzara, MA, Coles, AJ, on behalf of CARE-MS I and CAMMS03409 Investigators

$\textbf{Objective}$: Evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis (RRMS). $\textbf{Methods}$: Alemtuzumab-treated patients in CARE-MS I (NCT00530348) received treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::513f5aa1c25c9485c7ff12304426e952

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

Autor: Arnold, DL, Fisher, E, Brinar, VV, Cohen, JA, Coles, AJ, Giovannoni, G, Hartung, H-P, Havrdova, E, Selmaj, KW, Stojanovic, M, Weiner, HL, Lake, SL, Margolin, DH, Thomas, DR, Panzara, MA, Compston, DAS, CARE-MS I and CARE-MS II Investigators

$\textbf{Objective:}$ To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______109::697f278afc988c2c1c9585974b01820f
https://www.repository.cam.ac.uk/handle/1810/261768

Encephalitis and schizophrenia: a matter of words reply

Autor: Lennox, BR, Coles, AJ, Vincent, A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::092ff41c90540fc2ac7936d78024edd7
https://doi.org/10.1192/bjp.201.1.74a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.